Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8+ T Cell Therapy Plus Pembrolizumab in Advanced Solid Malignancies
NCT02757391Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2019
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in gastrointestinal cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of toxicity defined as grade 3 or 4 non-hematologic or grade 4 hematologic toxicity up to 24 weeks. Started Aug 2019; status: terminated.
02
Drugs
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT02757391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757391.